KRAS and familial pancreatic carcinoma: The authors performed a pyrosequencing assay for KRAS (codon 12) mutations and immunohistochemistry for MUC1/MUC2, and compared the histological diagnosis of the initial tumor and the remnant pancreatic cancer in the resected group.